Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464667 | 0.78 | PDE9A (0.49) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL29635217 | 0.78 | PDE9A (0.49) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL20505152 | 0.76 | ALDH1A1 (0.44) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL3680016 | 0.76 | AHR (0.55) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL16156592 | 0.76 | ALDH1A1 (0.44) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL8588245 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL2731190 | 0.76 | DRD2 (0.47) | ALDH1A1HSD17B10GPR3DRD2DRD4 | |
| SCHEMBL1029936 | 0.76 | MAPT (0.44) | ALDH1A1HSD17B10GPR3KDM4ESMN1; SMN2 | |
| SCHEMBL15486057 | 0.74 | CSNK2A1 (0.44) | ALDH1A1KDM4EDYRK1AHPGDLMNA | |
| SCHEMBL1622669 | 0.74 | PDE9A (0.62) | ALDH1A1HSD17B10GPR3KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135809-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-20170305906-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-9701676-B2 | Pro-neurogenic compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-07-11 | — | — | US | disclosed |
| EP-2887803-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140057900-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2014031986-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2012131297-A1 | PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE | BAELL JONATHAN BAYLDON (AU) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131297-A1 | PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE | BAELL JONATHAN BAYLDON (AU) | 2012-10-04 | — | — | WO | disclosed |
| EP-0439796-B1 | Indolylpropanols, process for their preparation, and their use and preparations containing them | BEIERSDORF LILLY GMBH (DE) | 1996-01-24 | — | — | EP | disclosed |
| US-5145849-A | Inotropic and antiarrythmia agents; sodium channel inhibitors | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| EP-0439796-A2 | Indolylpropanols, process for their preparation, and their use and preparations containing them | Beiersdorf-Lilly GmbH (DE) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057900-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | ALDH1A1 1252/4885HSD17B10 1152/4885GPR3 1899/4885 |
| US-20190135809-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | ALDH1A1 1252/4885HSD17B10 1152/4885GPR3 1899/4885 |
| US-20170305906-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | ALDH1A1 1252/4885HSD17B10 1152/4885GPR3 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.